Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.9952W HIGH $2.99
Volume
572.79 K
Value Traded
647.36 K
Short % Float
2.38%
Days to Cover
2.4
-8.47%Week
-27.52%1 Month
-18.18%3 Month
-14.96%6 Month
-78.49%5 Year
-61.53%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
51.57 M
EPS (TTM)
-0.19
P/E Ratio
-
Ent. Value
72.09 M
Total Shares
46.71 M
Float Shares
42.66 M
Insiders
9.45%
Institutions
9.27%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
HYFT Catalyst Timeline
Dated clinical, regulatory and corporate events for MindWalk Holdings Corp.
Catalyst Timeline
Dated clinical, regulatory & corporate events for MindWalk Holdings Corp.
286Total events
4Upcoming
49Tier-1 (high impact)
2020 to 2026Coverage
Upcoming catalysts 2
TBD
T2Timing Guidance
Subscribe to view catalyst details
TBD
T3IND Enabling Complete
Subscribe to view catalyst details
Event history 50
●Management ChangeCorporate
Kim Remizowski appointed to Board of Directors as independent director
●R&D DayPresentation
MindWalk participates in H.C. Wainwright 28th Annual Global Investment Conference
▲Debt Royalty FinancingCorporate
MindWalk enters binding commitment for US$30M unsecured credit facility with Sanabil (Cayman)
●Oral PresentationPresentation
First public demonstration of ReefIQ™ at AMD Advancing AI 2026
●Composition Patent FiledIP / Competition
Filed patent for high-dimensional biological data architecture
◆Oral PresentationPresentation
CEO Dr. Jennifer Bath to join Jones AI Day panel on future of AI drug discovery
●Platform ValidationPreclinical
Launch of ReefIQ biological context layer for AI drug discovery
▲Product LaunchReefIQPost-Market
MindWalk launches ReefIQ biological context layer for AI drug discovery
▲Preclinical PoCPreclinical
Preclinical data show cross-reactive antibody binding against all four dengue serotypes, corroborating HYFT computational prediction
denguesource ↗
▲Platform ValidationPreclinical
First public evidence that HYFT platform can generate reproducible discovery loop from computational prediction to in vivo validation
●Patent GrantedHYFTIP / Competition
Filed European patent application covering high-dimensional biological data structure underpinning HYFT Technology
●Patent GrantedIP / Competition
Filed European patent application covering high-dimensional biological data structure underpinning HYFT Technology
▲Quarterly UpdateCorporate
Reported fiscal 2026 revenue up 46% to C$15.6 million, net loss narrowed to C$13.9 million
◆Preclinical PoCPreclinical
Dengue vaccine program: binding confirmation results expected
Denguesource ↗
▲Platform ValidationPreclinical
Discovery and validation of monoclonal antibodies and intrabodies targeting pathogenic TDP-43
neurodegenerative diseasesource ↗
▲Preclinical PoCPreclinical
Discovery and validation of monoclonal antibodies and intrabodies targeting pathogenic TDP-43
amyotrophic lateral sclerosis, frontotemporal dementia, Alzheimer's diseasesource ↗
▲Platform ValidationPreclinical
External validation of MindWalk's platform capabilities in client-driven setting
◆Timing GuidancePresentation
Strategic update press release on first day of J.P. Morgan Healthcare Conference
▲Preclinical PoCPreclinical
Identified functional constraint across influenza A and B subtypes
influenzasource ↗
▲Platform ValidationPreclinical
Peer-reviewed study in ACS Biomacromolecules validates B Cell Llama platform
◆Preclinical PoCPreclinical
Preclinical planning completion anticipated early next quarter
denguesource ↗
▲Partnership / LicenseLensAICorporate
Signed first two contracted, recurring enterprise LensAI agreements
◆Quarterly UpdateCorporate
Q2 FY2026 financial results and business highlights conference call
▲Preclinical PoCPreclinical
GLP1 receptor agonist achieved receptor activation above semaglutide in vitro
metabolic control and longevitysource ↗
▲Preclinical PoCPreclinical
Identified conserved discontinuous epitope across all four dengue serotypes
denguesource ↗
●Trial InitiationTrial
Initiated formation of Cayman Islands corporation for segregated portfolios
◆Oral PresentationPresentation
CTO Dr. Dirk Van Hyfte to participate in fireside chat at AI Drug Discovery & Development Summit 2025
◆ATM ProgramCorporate
Board authorizes share repurchase program of up to 2.3 million common shares
◆Timing GuidancePresentation
Updates on lead selection for companion therapeutic and preclinical combination design parameters expected in coming quarters
longevity/agingsource ↗
▲Quarterly UpdateCorporate
Record Q1 FY2026 revenue of $7.6 million, 45% growth, margin expansion, narrowed losses
◆Oral PresentationPresentation
Company presentation at H.C. Wainwright 27th Annual Global Investment Conference
Past FDA Catalysts and PDUFA Decisions
How HYFT actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every HYFT program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| No insider trades match the selected filters. | |||||
Hedge Fund 13F Activity
Hedge Funds invested in HYFT
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in HYFT for Q2 2026. | ||||
Ownership Trends
HYFT Short Interest
Shares sold short, counted twice a month.
2.38%
Short % of Float
of tradable shares sold short
1.0M
Shares Sold Short
+43.3% vs prior count
2.4 Moderate
Days to Cover
trading days of normal volume to buy every short share back
430.9K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How HYFT ranks across every disease it competes in
Competitive Position is a premium feature
See how HYFT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialHYFT News
HYFT▼ -1.7%today
MindWalk Announces Agreement with Teva Australia to Support Defined Antibody-Discovery Workflows
MindWalk Holdings Corp. has entered a multi-year agreement with Teva Pharmaceuticals Australia to implement its ReefIQ™ technology. This collaboration aims to enhance antibody-discovery workflows using MindWalk's HYFT®-powered biological context layer and LensAI™ analytical capabilities. The AI will assist Teva Australia in making informed discovery decisions based on predictive analytics.
Read more →HYFTMindWalk Holdings Corp. Announces Leadership Update
MindWalk Holdings Corp. announced the departure of Thomas Lynch, PhD, as Chief Business Officer, effective October 16, 2026. CEO Jennifer Bath expressed gratitude for his contributions while emphasizing that the company's commercial priorities will remain unchanged. MindWalk is transitioning from technology development to deployment.
Read more →HYFTMindWalk Screens 890,634 Antibody Sequences for Immune Risk in Under Five Hours
MindWalk Holdings Corp. reported that its LensAI™ technology screened 890,634 antibody sequences in just 4 hours and 41 minutes. The screening was conducted on Amazon EC2 Hpc8a instances using 5th Gen AMD EPYC™ processors. This approach resulted in a cost reduction of up to 43% per sequence compared to similar Intel configurations.
Read more →HYFT▼ -7.4%on this news
MindWalk Holdings Corp. Strengthens Boston-Based Development Leadership as Pipeline Advances Toward Preclinical Efficacy Studies
MindWalk Holdings Corp. has announced the appointment of three senior leaders to enhance its Boston-based development team. This strategic move comes as the company progresses its pipeline towards preclinical efficacy studies, indicating a strong commitment to advancing its innovative Bio-Native AI initiatives.
Read more →HYFTMindWalk (NASDAQ: HYFT): Enterprise AI Has Found Its Ontology Layer. Biology Needs One Grounded in Biological Function
MindWalk Holdings Corp. (NASDAQ: HYFT) has announced the development of ReefIQ™, a biological context layer designed specifically for life sciences. This layer aims to address the limitations of current enterprise AI ontology layers, which do not adequately represent biological functions. The initiative seeks to provide a governed and model-agnostic framework for understanding biology.
Read more →HYFTMindWalk Appoints Kim Remizowski to Board of Directors as Independent Director
MindWalk Holdings Corp. has appointed Kim Remizowski as an independent director to its Board of Directors, effective September 29, 2026. He will also serve on the Audit Committee and the Compensation, Nomination and Governance Committee. This appointment is expected to enhance the company's governance and oversight capabilities.
Read more →HYFT▲ +8.1%on this newsshared move
MindWalk Brings OpenFold3 into Production in Minutes with AMD Inference Microservices on Vultr Kubernetes Engine
MindWalk Holdings Corp. has successfully deployed the OpenFold3 structure prediction model using AMD Inference Microservices on the Vultr Kubernetes Engine. This deployment, powered by AMD's MI325X GPUs, marks a significant achievement in the application of AI in life sciences. The collaboration with AMD and Vultr validates the effectiveness of AIM in production settings.
Read more →HYFT▼ -13.2%on this news
MindWalk Reports 21% Revenue Growth and Gross Margin Expansion to 59% in Fiscal First Quarter 2027
MindWalk Holdings Corp. reported a strong financial performance for its fiscal first quarter of 2027, with a 21.3% increase in revenue year-over-year, reaching $3.8 million. The company also saw a significant gross profit increase of 47.1%, leading to an expanded gross margin of 58.6%. This quarter marks the commercial launch of their ReefIQ™ data platform.
Read more →HYFTMindWalk Lands Binding Commitment for US$30 Million Unsecured Credit Facility to Fund Biologics Programs and Commercial Expansion
MindWalk Holdings Corp. has secured a $30 million unsecured credit facility from Sanabil (Cayman). This funding is aimed at supporting the company's biologics programs and commercial growth. The facility features a fixed annual interest rate of 7.00%, which will apply only to the drawn amounts, providing flexibility for financial management.
Read more →HYFTMindWalk to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
MindWalk Holdings Corp. (HYFT) will participate in the H.C. Wainwright 28th Annual Global Investment Conference from September 14-16, 2026. A pre-recorded fireside chat featuring CEO Dr. Jennifer Bath will be available for registered attendees. This event aims to address investor inquiries regarding sustainable growth opportunities.
Read more →HYFTMindWalk Holdings Corp. to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2027 on September 14, 2026
MindWalk Holdings Corp. has announced its plans to report financial results for the first quarter of fiscal year 2027 on September 14, 2026. The company will also host a conference call at 5:00 p.m. Eastern Time, which will include a management presentation and a question-and-answer session. This event aims to provide insights into the company's performance and future direction.
Read more →HYFT▲ +15.3%on this news
A Small AI Company Just Took the Stage at One of the Biggest Events in Computing, and It Points to Where Drug Discovery Is Headed
MindWalk Holdings Corp. presented its ReefIQ platform at the Advancing AI 2026 event, emphasizing the importance of biological context in AI drug discovery. The demonstration highlighted how ReefIQ reconnects fragmented data to enhance AI reasoning. This innovation positions MindWalk among key players in the rapidly evolving AI-drug-discovery landscape, which is gaining investor attention.
Read more →HYFT▲ +15.3%on this newsshared move
MindWalk Showcases ReefIQ™ for AI Drug Discovery at AMD Advancing AI
MindWalk Holdings Corp. has publicly demonstrated ReefIQ™, its AI drug discovery tool, at AMD's Advancing AI event in San Francisco. This marks the first time ReefIQ™ has been showcased, emphasizing its biological context layer for enhancing AI applications in drug discovery. The demonstration is part of a broader collaboration with AMD.
Read more →HYFT▼ -18.1%on this newsshared move
An AI Biotech Just Reported a 46% Revenue Jump and Its First Recurring Platform Contracts, as Its Pivot Starts Showing Up in the Numbers
MindWalk Holdings Corp. reported a 46% increase in revenue for fiscal 2026, reaching C$15.6 million, alongside its first contracted recurring revenue. The company's net loss narrowed significantly, showcasing a shift from project-based work to a more sustainable software business model. The report indicates a positive trend in financial performance, although risks remain due to the company's history of losses and the preliminary nature of the results.
Read more →HYFT▼ -18.1%on this newsshared move
MindWalk Holdings Corp. Reports Fiscal 2026 Results: Revenue Up 46% as the Company Completes Its Pivot to Bio-Native AI Infrastructure
MindWalk Holdings Corp. reported a 46% increase in revenue for fiscal 2026, marking a successful transition to deploying its Bio-Native AI technology. The company also saw an expansion in gross margins and a significant reduction in net loss. Additionally, it divested a non-core business, further streamlining its operations.
Read more →HYFTMindWalk Holdings Corp. to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2026 on July 22, 2026
MindWalk Holdings Corp. has announced it will report its financial results for the fourth quarter and full fiscal year 2026 on July 22, 2026. The company will host a conference call at 5:00 p.m. Eastern Time, which will include a management presentation and a question-and-answer session. A press release with the financial results will be issued prior to the call.
Read more →HYFTMindWalk Holdings Corp. (NASDAQ: HYFT) Added to the Russell 3000E Index, Expanding Institutional Investment Opportunity
MindWalk Holdings Corp. has been officially added to the Russell 3000E Index, which is expected to expand its institutional investment opportunities. This inclusion highlights the company's growing recognition in the market. Investors may see increased interest in the stock as a result of this development.
Read more →HYFTMindWalk (NASDAQ: HYFT) Files Patent for High-Dimensional Biological Data Architecture Powering AI Drug Discovery
MindWalk has filed a patent for a new high-dimensional biological data architecture aimed at enhancing AI drug discovery processes. This innovation is expected to improve the efficiency and effectiveness of drug development. The details of the technology and its potential applications in the biopharma sector remain to be fully disclosed.
Read more →HYFTMindWalk (NASDAQ: HYFT) CEO Dr. Jennifer Bath to Join Absci (NASDAQ: ABSI) and a Leading AI Compute Provider on Jones AI Day Panel on the Future of AI Drug Discovery
Dr. Jennifer Bath, CEO of MindWalk, is set to participate in a panel discussion on AI drug discovery during Jones AI Day. She will join representatives from Absci and a leading AI compute provider. The event aims to explore the future of AI in the pharmaceutical industry.
Read more →HYFTMindWalk Holdings Corp. (NASDAQ: HYFT) Launches ReefIQ™, a Biological Context Layer for AI Drug Discovery
MindWalk Holdings Corp. has announced the launch of ReefIQ™, a new biological context layer designed to enhance AI drug discovery. This innovative tool aims to improve the efficiency and effectiveness of drug development processes. The announcement highlights the company's commitment to integrating advanced technology in biopharmaceutical research.
Read more →About MindWalk Holdings Corp.
BIOPHARMAWATCH ELITE PLUS
Trade the next HYFT catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime